Texas Cancer Institute Adopts Kallisio’s Patient-Specific Stentra™ Oral Immobilization Solution as Standard-of-Care Following Successful Pilot
Kallisio, a leader in patient-specific solutions for radiation oncology, today announced Texas Cancer Institute (TCI) has transitioned from a pilot evaluation to clinical use of Stentra™ for precision head and neck cancer radiation therapy. This follows an observational case series in which the use of Kallisio’s Stentra system supported zero missed treatment days across all evaluated patients.
Kallisio Stentra™ Named “Best New Radiology Technology Solution” in 2026 MedTech Breakthrough Awards Program
Kallisio, a company focused on advancing precision oncology through patient-specific, technology-enabled solutions, today announced that Stentra™ has received “Best New Radiology Technology Solution” in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market.
Kallisio Receives CE Mark for Stentra™ Precision Oral Immobilization System
Kallisio, a company focused on advancing precision oncology through patient-specific, technology-enabled solutions, today announced CE certification under the European Union Medical Device Regulation (EU MDR 2017/745) for its Stentra intraoral positioning system. This certification enables commercialization within the European Economic Area, with initial deployment planned in Germany through selected clinical pilot sites.
Kallisio Announces Clinical Implementation of Its Patient-Specific Stentra™ System
Kallisio, a company developing patient-specific precision-therapy solutions, announced that it has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head and neck cancer radiation therapy.
Kallisio Patient-tailored Oral Stent for Head and Neck Cancer (HNC) Treatment Receives FDA Clearance
Kallisio, focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients. Customized for each patient, the Stentra oral immobilization stent effectively directs radiation to the target tumor area while reducing harmful impact to surrounding tissue.
